Robert W. Robey

Oct 23, 2023 | biorxiv.org | John Quinlan |Robert W. Robey |Joanna Thomas |Collin T. Inglut

AbstractATP-binding cassette (ABC) transporters expressed at the blood-brain barrier (BBB) impede delivery of therapeutic agents to the brain, including agents to treat neurodegenerative diseases and primary and metastatic brain cancers. Two transporters, P-glycoprotein (P-gp, ABCB1) and ABCG2, are highly expressed at the BBB and are responsible for the efflux of numerous clinically useful chemotherapeutic agents, including irinotecan, paclitaxel, and doxorubicin.

Jul 29, 2023 | fredericknewspost.com | Robert W. Robey

On June 20, the Frederick Planning Commission had a workshop on the Brickworks Project proposed for 184 E. South St.The project is a multiuse development with up to 1,260 residential units and a 130,000-square-foot commercial/retail Neighborhood Center. Historically, bricks were manufactured there using coal fuel from 1891 to 1947. Clay was mined in the central portion of the site. These pits were later used to dispose of waste from brick manufacturing and city solid wastes.

Feb 15, 2023 | biorxiv.org | Robert W. Robey |Christina M. Fitzsimmons |Wilfried M. Guiblet |William Frye

New Results doi: https://doi.org/10.1101/2022.10.07.511310 AbstractHistone deacetylase inhibitors (HDACis) are part of a growing class of epigenetic therapies used for the treatment of cancer. While elevated levels of the efflux pump P-gp are associated with in vitro resistance to romidepsin, this mechanism does not translate to the clinic.